MNKD logo

MannKind Corporation (MNKD)

$4.04

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MNKD

Market cap

$1.25B

EPS

-0.07

P/E ratio

--

Price to sales

2.42

Dividend yield

--

Beta

1.085839

Price on MNKD

Previous close

$4.09

Today's open

$4.06

Day's range

$4.03 - $4.20

52 week range

$2.23 - $6.51

Profile about MNKD

CEO

Michael E. Castagna

Employees

407

Headquarters

Danbury, CT

Exchange

NASDAQ Global Market

Shares outstanding

308950166

Issue type

Common Stock

MNKD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MNKD

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

news source

GlobeNewsWire • Jun 23, 2026

news preview

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

news source

GlobeNewsWire • Jun 5, 2026

news preview

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

news source

GlobeNewsWire • Jun 3, 2026

news preview

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027.

news source

Seeking Alpha • Jun 3, 2026

news preview

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market

MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into children and adolescents.

news source

MarketBeat • May 31, 2026

news preview

US FDA approves MannKind's inhaled insulin for children

The U.S. Food and Drug Administration has approved expanded use ​of MannKind's inhaled rapid-acting insulin ‌in children with diabetes, offering patients under 18 years of age a ​needle-free treatment option, the ​company said on Friday.

news source

Reuters • May 29, 2026

news preview

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

news source

GlobeNewsWire • May 29, 2026

news preview

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

news source

Seeking Alpha • May 29, 2026

news preview

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes

news source

GlobeNewsWire • May 29, 2026

news preview

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS

news source

GlobeNewsWire • May 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MannKind Corporation

Open an M1 investment account to buy and sell MannKind Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MNKD on M1